Glycyrrhetic Acid Derivative TY501 Protects Against Lithocholic Acid–Induced Cholestasis

The aim of the study is to investigate the protective effects of TY501 against LCA-induced cholestasis in mice and to explore the potential mechanisms. It was demonstrated that TY501(5, 15 or 45 mg/kg, i.g.) can markedly reduced the level of ALT, AST and ALP which increased by LCA treatment. Meanwhile, TY501 also lowered total bile acids, total bilirubin and total cholesterol levels in serum. Furthermore, TY501 can protect HepG2 cell cultures from LCA-induced cytotoxicity. RT-PCR and Western Blot analysis showed that TY501 recovered the expression of BSEP, MRP2 and NTCP which were down-regulated by LCA. Moreover, mRNA and protein of FXR was also observed in TY501 treated mice significantly accumulation in nucleus. Taken together, It can be concluded that TY501 exerted beneficial effects on LCA-induced cholestasis, possibly via activation of FXR mediated upregulation of BSEP, MRP2 and NTCP.

[1]  D. Richard,et al.  Effects of Bariatric Surgery on Energy Homeostasis. , 2017, Canadian journal of diabetes.

[2]  M. Huang,et al.  Schisandrol B protects against cholestatic liver injury through pregnane X receptors , 2017, British journal of pharmacology.

[3]  Yi-ming Li,et al.  Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor-mediated regulation of Bsep and Mrp2. , 2017, Canadian journal of physiology and pharmacology.

[4]  P. Chiba,et al.  Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury. , 2017, Journal of hepatology.

[5]  Huijun Sun,et al.  Dioscin protects against ANIT-induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats. , 2016, Toxicology and applied pharmacology.

[6]  X. Qian,et al.  Yinzhihuang attenuates ANIT-induced intrahepatic cholestasis in rats through upregulation of Mrp2 and Bsep expressions , 2016, Pediatric Research.

[7]  C. Still,et al.  Bile Acids, FXR, and Metabolic Effects of Bariatric Surgery , 2016, Journal of obesity.

[8]  Jin-jian Lu,et al.  A Systematic Review of the Anticancer Properties of Compounds Isolated from Licorice (Gancao) , 2015, Planta Medica.

[9]  M. Huang,et al.  Oleanolic acid attenuates obstructive cholestasis in bile duct-ligated mice, possibly via activation of NRF2-MRPs and FXR antagonism. , 2015, European journal of pharmacology.

[10]  I. Albert,et al.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.

[11]  H. Jaeschke,et al.  Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. , 2014, Toxicology letters.

[12]  M. Huang,et al.  Low Dose of Oleanolic Acid Protects against Lithocholic Acid–Induced Cholestasis in Mice: Potential Involvement of Nuclear Factor-E2-Related Factor 2-Mediated Upregulation of Multidrug Resistance-Associated Proteins , 2014, Drug Metabolism and Disposition.

[13]  Huijun Sun,et al.  Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. , 2012, Toxicology and applied pharmacology.

[14]  H. Jaeschke,et al.  Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity. , 2012, Toxicology and applied pharmacology.

[15]  Y. Sugiyama,et al.  4-Phenylbutyrate modulates ubiquitination of hepatocanalicular MRP2 and reduces serum total bilirubin concentration. , 2012, Journal of hepatology.

[16]  Yanqiao Zhang,et al.  Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. , 2012, Molecular endocrinology.

[17]  G. Van den Berghe,et al.  Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression , 2011, Hepatology.

[18]  N. Araníbar,et al.  Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  U. Beuers,et al.  The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. , 2011, Current drug targets.

[20]  P. Siersema,et al.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease , 2011, Gut.

[21]  B. M. Forman,et al.  Farnesoid X receptor alleviates age‐related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription , 2009, Hepatology.

[22]  U. Beuers,et al.  Primary biliary cirrhosis , 2009, Seminars in Immunopathology.

[23]  C. Klaassen,et al.  ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  Ming Yan,et al.  Prevention of free fatty acid–induced hepatic lipotoxicity by 18β‐glycyrrhetinic acid through lysosomal and mitochondrial pathways , 2008, Hepatology.

[25]  Hossein Hosseinzadeh,et al.  Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive Compounds , 2008, Phytotherapy research : PTR.

[26]  K. Zatloukal,et al.  Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress , 2007, Drug Metabolism and Disposition.

[27]  J. Ward,et al.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. , 2007, Carcinogenesis.

[28]  G. Gerken,et al.  Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. , 2006, Journal of hepatology.

[29]  K. Zatloukal,et al.  Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. , 2006, The American journal of pathology.

[30]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.